Search results for "microbial"

showing 10 items of 2041 documents

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe

2016

Transmitted human immunodeficiency virus drug resistance in Europe is stable at around 8%. The impact of baseline mutation patterns on susceptibility to antiretroviral drugs should be addressed using clinical guidelines. The impact on baseline susceptibility is largest for nonnucleoside reverse transcriptase inhibitors.

MaleHuman immunodeficiency virus 1EtravirineRNA directed DNA polymerase inhibitordarunavirHIV InfectionsSettore MED/42 - Igiene Generale E Applicata:Disciplines and Occupations::Health Occupations::Medicine::Public Health [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Salud públicageneticsInhibidores de proteasas:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Prevalence [Medical Subject Headings]atazanavirmedia_commontransmission:Geographicals::Geographic Locations::Europe [Medical Subject Headings]3. Good healthmicrobial sensitivity testpriority journalEurope ; HIV-1 ; antiretroviral therapy ; drug resistance ; transmissionHIV/AIDSlamivudineReverse Transcriptase Inhibitors/pharmacologyanti human immunodeficiency virus agentDrugMicrobiology (medical)medicine.medical_specialtyantiviral susceptibility:Phenomena and Processes::Genetic Phenomena::Genetic Variation::Mutation [Medical Subject Headings]media_common.quotation_subjectantiretroviral therapy030106 microbiologyHIV Infections/drug therapy:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents::Anti-Retroviral Agents::Reverse Transcriptase Inhibitors [Medical Subject Headings]Microbial Sensitivity TestsRILPIVIRINEArticleEFAVIRENZ03 medical and health sciencestransmitted drug resistanceSDG 3 - Good Health and Well-beingHumansTransmissionhuman:Phenomena and Processes::Physiological Phenomena::Pharmacological Phenomena::Drug Resistance [Medical Subject Headings]REVERSE-TRANSCRIPTASE INHIBITORSRilpivirinaINTEGRASEMUTATIONSabacavirmajor clinical studyVirologyInfecciones por VIHRegimenAntiretroviral therapy; Drug resistance; Europe; HIV-1; Transmission; Medicine (all); Microbiology (medical); Infectious DiseaseschemistryDrug resistance:Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds 1-Ring::Oxazines::Benzoxazines [Medical Subject Headings]MutationHIV-10301 basic medicinenevirapineDrug resistanceCommunicable diseases:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Confidence Intervals [Medical Subject Headings]chemistry.chemical_compoundantiviral therapyINFECTIONMedicine and Health SciencesPrevalence:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires [Medical Subject Headings]ViralNon-U.S. Gov'tReverse-transcriptase inhibitorantiretrovirus agentResearch Support Non-U.S. Gov'tMedicine (all)Human immunodeficiency virus infected patientMiddle AgedvirologyPREVALENCEAntiretroviral therapyEncuestas y CuestionariosANTIRETROVIRAL TREATMENTEuropeInfectious DiseasesHIV-1/drug effectsHIV Protease Inhibitors/pharmacologyRilpivirineReverse Transcriptase Inhibitors:Diseases::Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infections [Medical Subject Headings]FemaleHIV drug resistancemedicine.drugAdultHuman immunodeficiency virus proteinase inhibitor:Chemicals and Drugs::Organic Chemicals::Nitriles::Rilpivirine [Medical Subject Headings]EfavirenzAnti-HIV AgentsResearch SupportResistencia a medicamentosSettore MED/17 - MALATTIE INFETTIVEantiviral resistanceInternal medicineAnti-HIV Agents/pharmacologyDrug Resistance ViralJournal Articlemedicine:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protease Inhibitors [Medical Subject Headings]abacavir plus lamivudineEuropa (Continente)Antiretroviral therapy; Drug resistance; Europe; HIV-1; Transmission; Adult; Anti-HIV Agents; Drug Resistance Viral; Europe; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Prevalence; Reverse Transcriptase Inhibitors; Microbiology (medical); Infectious DiseasesemtricitabinenonhumanIntervalos de confianzadrug resistanceMutaciónAntiretroviral therapy; Drug resistance; Europe; HIV-1; Transmissionbusiness.industryHIVpredictionInhibidores de la transcriptasa inversaHIV Protease InhibitorsHuman immunodeficiency virus 1 infectiontenofovirINDIVIDUALSDrug Resistance Viral/geneticsBenzoxazinasETRAVIRINEdrug effects3121 General medicine internal medicine and other clinical medicinePrevalenciabusiness
researchProduct

Two versus three doses of a meningococcal C conjugate vaccine concomitantly administered with a hexavalent DTaP-IPV-HBV/Hib vaccine in healthy infant…

2007

The immunogenicity and reactogenicity of a meningococcal serogroup C (MenC) conjugate vaccine given concomitantly with DTaP-IPV-HBV/Hib vaccine according to a two- or three-dose schedule in healthy infants was evaluated. At 1 month post-vaccination, 98% (two doses) and 100% (three doses) of subjects had serum bactericidal antibody using human complement assay (hSBA) titres > or =1:8; at 12 months of age > or =89% of subjects in each group remained seroprotected. Induction of immunological memory, as evaluated by administration of a meningococcal serogroup A/C polysaccharide vaccine challenge dose, was similar for both regimens and no interference was observed in the immune response to MenC …

MaleImmunization SecondaryMeningococcal VaccinesMeningococcal vaccineMeningitis Meningococcalmedicine.disease_causeMeningococcal diseaseConjugate vaccinemedicineHumansHepatitis B VaccinesVaccines CombinedHepatitis B AntibodiesBacterial CapsulesDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesHepatitis B virusReactogenicityMicrobial ViabilityVaccines ConjugateGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityNeisseria meningitidisPublic Health Environmental and Occupational HealthInfantmedicine.diseaseVirologyAntibodies BacterialPoliovirus Vaccine InactivatedInfectious DiseasesHib vaccineImmunologyMolecular MedicineFemalebusinessImmunologic MemoryVaccine
researchProduct

DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?

2014

Background. Morbidity and mortality for critically ill patients with infections remains a global healthcare problem. We aimed to determine whether α-lactam antibiotic dosing in critically ill patients achieves concentrations associated with maximal activity and whether antibiotic concentrations affect patient outcome.Methods. This was a prospective, multinational pharmacokinetic point-prevalence study including 8 α-lactam antibiotics. Two blood samples were taken from each patient during a single dosing interval. The primary pharmacokinetic/pharmacodynamic targets were free antibiotic concentrations above the minimum inhibitory concentration (MIC) of the pathogen at both 50% (50% f TMIC) an…

MaleInternational CooperationAntibioticsadverse eventintensive care unitlaw.invention0302 clinical medicinemeropenemModels[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesadverse events; continuous infusion; extended infusion; pharmacodynamics; pharmacokinetics; Aged; Anti-Bacterial Agents; Bacterial Infections; Blood Chemical Analysis; Female; Humans; Intensive Care Units; International Cooperation; Male; Microbial Sensitivity Tests; Middle Aged; Models Statistical; Prospective Studies; Treatment Outcome; beta-Lactams; Critical Illnessantibiotic therapyProspective Studiesamoxicillin plus clavulanic acidComputingMilieux_MISCELLANEOUSbeta lactam antibioticAPACHE0303 health sciencescritical illneadultclinical trial3. Good healthcontinuous infusion; extended infusion; adverse events; pharmacokinetics; pharmacodynamics.antiinfective agent[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitologypriority journaldisease severitybeta-Lactamstatistical model Agedprospective studyHumanMicrobiology (medical)medicine.medical_specialtydrug exposureCritical IllnessImmunologybloodstream infectionMicrobial Sensitivity Testspiperacillin plus tazobactambeta-LactamsMicrobiologybeta lactam abdominal infection03 medical and health sciencescritically ill patientIntensive careAnti-Bacterial AgentcefepimepharmacodynamicsHumansDosingAdverse effectAgedModels Statistical030306 microbiologyOdds ratiomajor clinical studymortalityantibiotic sensitivityceftriaxoneProspective Studiemulticenter studypharmacodynamics.ampicillinBlood Chemical AnalysisCeftazidimeSettore MED/41 - AnestesiologiaInterquartile rangelaw030212 general & internal medicinepharmacokineticlung infectionMicrobial Sensitivity TestarticleBacterial InfectionsMiddle AgedStatisticalcontinuous infusionIntensive care unitAnti-Bacterial Agentsextended infusionIntensive Care UnitsInfectious DiseasesTreatment Outcomeadverse events; continuous infusion; extended infusion; pharmacodynamics; pharmacokinetics; Aged; Anti-Bacterial Agents; Bacterial Infections; Blood Chemical Analysis; Female; Humans; Intensive Care Units; International Cooperation; Male; Microbial Sensitivity Tests; Middle Aged; Models Statistical; Prospective Studies; Treatment Outcome; beta-Lactams; Critical Illness; Microbiology (medical); Infectious Diseasescefazolin[SDV.IMM]Life Sciences [q-bio]/Immunologyblood samplingFemalepharmacokineticsmedicine.drugmedicine.drug_classprevalencedoripenemminimum inhibitory concentrationBacterial InfectionInternal medicinemedicinecontrolled studyblood analysibusiness.industryBlood Chemical Analysiadverse eventsSurgerypharmacodynamicdrug blood levelbusiness
researchProduct

Stool Phospholipid Signature is Altered by Diet and Tumors

2014

Intake of saturated fat is a risk factor for ulcerative colitis (UC) and colon cancer. Changes in the microbiota have been implicated in the development of UC and colon cancer. The host and the microbiota generate metabolites that may contribute to or reflect disease pathogenesis. We used lipid class specific quantitative mass spectrometry to assess the phospholipid (PL) profile (phosphatidylcholine [PC], phosphatidylethanolamine [PE], phosphatidylinositol [PI], phosphatidylserine [PS]) of stool from mice fed a high fat (HFD) or control diet with or without induction of colitis-associated tumors using azoxymethane and dextran sodium sulfate. The microbiota was assessed using qPCR for severa…

MaleLifestyle Causes of CancerCarcinogenesisPhysiologySaturated fatlcsh:MedicineFeceschemistry.chemical_compound0302 clinical medicineMacromolecular Structure AnalysisMedicine and Health SciencesPrevotellalcsh:SciencePhospholipids0303 health sciencesLipid AnalysisMultidisciplinaryEcologybiologyMicrobiotaCancer Risk FactorsClostridium leptumPhosphatidylserineColitis3. Good healthPhysiological ParametersOncologyBiochemistryMedical MicrobiologyNutritional Correlates of CancerColonic NeoplasmsFemale030211 gastroenterology & hepatologyAnatomyResearch Articlemedicine.medical_specialtyColonPhospholipidGastroenterology and HepatologyDiet High-FatMicrobiologyMicrobial Ecology03 medical and health sciencesInternal medicineBiomarkers TumormedicineAnimalsObesityColitisMolecular Biology030304 developmental biologyColorectal CancerPhosphatidylethanolamineAzoxymethaneBody Weightlcsh:RBiology and Life SciencesCancers and Neoplasmsmedicine.diseasebiology.organism_classificationMice Inbred C57BLGastrointestinal TractEndocrinologychemistrylcsh:QMicrobiomePhysiological ProcessesDigestive SystemPLoS ONE
researchProduct

VEB-1 in Achromobacter xylosoxidans from Cystic Fibrosis Patient, France

2006

Multidrug-resistant Achromobacter xylosoxidans was recovered from the sputum of a patient with cystic fibrosis. The VEB-1 extended-spectrum β-lactamase was detected on a class 1 integron. This first report of a VEB-1–producing isolate in this population requires further investigation to determine its distribution.

MaleMESH : Molecular Sequence DataintegronMESH: beta-Lactamaseslcsh:MedicineMESH: Base Sequence[ SDV.MP.BAC ] Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyIntegronCystic fibrosisIntegronscystic fibrosisComputingMilieux_MISCELLANEOUSMESH: Microbial Sensitivity Tests0303 health scienceseducation.field_of_studybiologyEscherichia coli ProteinsMESH : beta-LactamasesAchromobacter denitrificansdispatchAchromobacter xylosoxidansMESH: Integrons3. Good healthMESH : Achromobacter denitrificansFrancemedicine.symptomAchromobacter xylosoxidansMESH : IntegronsMESH: Cystic FibrosisAdolescentMESH : MaleMolecular Sequence DataPopulationMicrobial Sensitivity Testsbeta-LactamasesMicrobiologylcsh:Infectious and parasitic diseases03 medical and health sciencesMESH : AdolescentMESH : Cystic FibrosismedicineHumansBase sequencelcsh:RC109-216education030304 developmental biologyMESH: AdolescentMESH: HumansMESH: Molecular Sequence DataBase Sequence030306 microbiologybusiness.industryMESH : Humanslcsh:RExtended-spectrum beta-lactamase VEB-1biology.organism_classificationmedicine.disease[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyMESH: MaleMESH: Achromobacter denitrificansAchromobacter denitrificansbiology.proteinSputumMESH : Base SequenceMESH : Microbial Sensitivity Tests[SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologybusinessEmerging Infectious Diseases
researchProduct

Colonization of pressure ulcers by multidrug-resistant microorganisms in patients receiving home care

2011

Colonization and/or infection with multidrug-resistant microorganisms (MDRO) of pressure ulcers in patients receiving care at home have seldom been investigated. The objective of this study was to assess the prevalence of MDRO colonization in pressure ulcers of patients receiving home care in Palermo, Italy. Vancomycin-resistant Enterococcus (VRE), methicillinresistant Staphylococcus aureus (MRSA), and multidrug-resistant Gram-negative bacilli (MDRGN) were isolated, identifi ed, and characterized from pressure ulcers and selected home environment surfaces. Thirty-two patients were enrolled, of whom 12 were under antimicrobial therapy. Five patients had been admitted to hospital in the prece…

MaleMethicillin-Resistant Staphylococcus aureusMicrobiology (medical)medicine.medical_specialtymultidrug-resistantDrug resistancemedicine.disease_causeDrug Resistance Multiple BacterialInternal medicineGram-Negative BacteriaEpidemiologyHumansMedicineIn patientColonizationIntensive care medicineAgedAged 80 and overPressure UlcerGeneral Immunology and Microbiologybiologybusiness.industrySkin Diseases BacterialGeneral MedicineMiddle Agedbiochemical phenomena metabolism and nutritionbacterial infections and mycosesbiology.organism_classificationAntimicrobialHome Care ServicesAnti-Bacterial AgentsMultiple drug resistanceInfectious DiseasesItalyEnterococcusStaphylococcus aureusFemalehome carebusinessEnterococcusScandinavian Journal of Infectious Diseases
researchProduct

Methicillin-resistant Staphylococcus aureus colonization: a three-year prospective study in a neonatal intensive care unit in Italy.

2014

Background: Methicillin resistant Staphylococcus aureus (MRSA) is a major etiological agent of infection in neonatal intensive care units (NICUs). Routes of entry of this organism can be different and the transmission pathway complex. Colonized neonates are the main endogenous reservoir. Methods and Results: We conducted a prospective three-year study on MRSA colonization recruiting 722 neonates admitted between 2009 and 2012. Nasal swabs were cultured weekly and MRSA isolates were submitted to molecular typing. The annual incidence density of acquisition of MRSA ranged from a maximum of 20.2 cases for 1000 patient-days during the first year to a minimum of 8.8 cases in the second one to ra…

MaleMethicillin-Resistant Staphylococcus aureusSettore MED/07 - Microbiologia E Microbiologia ClinicaPediatricsmedicine.medical_specialtyMeticillinNeonatal intensive care unitInfectious Disease ControlClinical Research DesignEpidemiologyBacterial diseasesPrevalenceColony Count Microbiallcsh:MedicineDrug resistanceSettore MED/42 - Igiene Generale E Applicatamedicine.disease_causePediatricsInfectious Disease EpidemiologySettore MED/01 - Statistica MedicaSettore MED/38 - Pediatria Generale E SpecialisticaIntensive careIntensive Care Units NeonatalNosocomial infectionsmedicineHumansColonizationProspective Studieslcsh:ScienceMolecular EpidemiologyMultidisciplinarybusiness.industrylcsh:RInfant NewbornOutbreakStaphylococcal Infectionsbacterial infections and mycosesMethicillin-resistant Staphylococcus aureusMolecular TypingMethicillin resistant Staphylococcus aureus neonatal intensive care unitMedicineInfectious diseasesFemalelcsh:QNeonatologybusinessmedicine.drugResearch ArticlePLoS ONE
researchProduct

Chronic Obstructive Pulmonary Disease Lung Microbiota Diversity May Be Mediated by Age or Inhaled Corticosteroid Use

2015

We read with great interest the paper by Garcia-Nunez et al. ([1][1]) published in the December 2014 issue of this journal, where the authors investigated the sputum microbiota of chronic obstructive pulmonary disease (COPD) patients. The authors found decreased microbial diversity in patients with

MaleMicrobiology (medical)Microbial diversitymedia_common.quotation_subjectPulmonary diseasePulmonary Disease Chronic ObstructivemedicineAnimalsHumansIn patientLetters to the Editormedia_commonCOPDLungBacteriabusiness.industryMicrobiotamedicine.diseasehumanitiesrespiratory tract diseasesmedicine.anatomical_structureImmunologySputumFemaleCorticosteroid usemedicine.symptombusinessDiversity (politics)Journal of Clinical Microbiology
researchProduct

Prevention of the post-chemotherapy relapse of tuberculous infection by combined immunotherapy

2008

Summary We report that a recently developed combined immunotherapy (CIT) has the capacity to prevent a spontaneous relapse of replicating Mycobacterium tuberculosis bacilli in the lungs of BALB/c, C57Bl/6 or C3H/HeJ strains of mice, following 4 weeks of non-sterilising treatment with isoniazid and rifampicin. The CIT regimen, represented by recombinant IFNγ, anti-α crystalline monoclonal IgA antibody and IL-4 neutralizing polyclonal antibody, reduced the 8-week relapse of viable bacterial counts in the lungs most significantly, when CIT was inoculated during the 5th week post infection, i.e. during the 3rd week of chemotherapy. Although CIT enhanced lung granuloma area, nitric oxide, cytoki…

MaleMicrobiology (medical)TuberculosisTuberculosiAntibodiemedicine.medical_treatmentImmunologyAntitubercular AgentsColony Count MicrobialMicrobiologyAntibodiesMycobacterium tuberculosisInterferon-gammaMiceAdjuvants ImmunologicRecurrencemedicineAnimalsalpha-CrystallinsRelapseTuberculosis PulmonaryCytokineMice Inbred BALB CMice Inbred C3HChemotherapyLungbiologybusiness.industryTuberculosis; Cytokines; Antibodies; Immunotherapy; RelapseIsoniazidMycobacterium tuberculosisImmunotherapybiology.organism_classificationmedicine.diseaseCombined Modality TherapyRecombinant ProteinsImmunoglobulin AMice Inbred C57BLRegimenInfectious Diseasesmedicine.anatomical_structureModels AnimalImmunologyInterleukin-4ImmunotherapybusinessRifampicinmedicine.drugTuberculosis
researchProduct

Efficacy of posaconazole and amphotericin B in experimental invasive pulmonary aspergillosis in dexamethasone immunosuppressed rats

2007

Objectives: Invasive pulmonary aspergillosis is associated with high mortality. To assess new antifungal therapy options, animal models have to be developed to assess, in an appropriate setting, the activity of new drugs. Methods: Male albino CD rats (125–150 g) were fed with a protein-free diet and received dexamethasone thrice weekly subcutaneously during the whole experiment. After 2 weeks, an inoculum of 10 6 conidia of Aspergillus fumigatus (H11-20) was injected intratracheally. Antifungal treatment was initiated and continued for a total of 7 days. Animals were grouped in numbers of 10. One group of animals served as untreated control, whereas the others were treated with amphotericin…

MaleMicrobiology (medical)medicine.medical_specialtyPosaconazoleAntifungal AgentsDosemedicine.drug_classMicrobial Sensitivity TestsBiologyAspergillosisGastroenterologyDexamethasoneAspergillus fumigatusRats Sprague-DawleyImmunocompromised HostDrug Resistance FungalAmphotericin BAmphotericin BInternal medicinemedicineAnimalsPharmacology (medical)DexamethasoneMycosisPharmacologyDose-Response Relationship DrugAspergillus fumigatusAspergillosis Allergic BronchopulmonaryTriazolesbiology.organism_classificationmedicine.diseaseRatsInfectious DiseasesImmunologyCorticosteroidDrug Therapy Combinationmedicine.drugJournal of Antimicrobial Chemotherapy
researchProduct